Page 250 - Haematologica March 2020

B. Federmann et al.
RNAscope in situ hybridization confirms
mRNA integrity in formalin-fixed, paraffin- embedded cancer tissue samples. Oncotarget. 2017;8(55):93392-93403.
42. Wong ML, Medrano JF. Real-time PCR for mRNA quantitation. BioTechniques. 2005;39(1):75-85.
43. Lord M, Wasik AM, Christensson B, et al. The utility of mRNA analysis in defining SOX11 expression levels in mantle cell lym- phoma and reactive lymph nodes. Haematologica. 2015;100(9):e369-372.
44. Balsas P, Palomero J, Eguileor A, et al. SOX11 promotes tumor protective microenviron- ment interactions through CXCR4 and FAK
regulation in mantle cell lymphoma. Blood.
2017;130(4):501-513.
45. Wang X, Bjorklund S, Wasik AM, et al. Gene
expression profiling and chromatin immunoprecipitation identify DBN1, SET- MAR and HIG2 as direct targets of SOX11 in mantle cell lymphoma. PloS One. 2010;5(11):e14085.
46. Rudelius M, Rosenfeldt MT, Leich E, et al. Inhibition of focal adhesion kinase over- comes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenviron- ment. Haematologica. 2018;103(1):116-125.
47. Ferrando AA. SOX11 is a mantle cell lym- phoma oncogene. Blood. 2013;121(12):
2169-2170.
48. Beekman R, Amador V, Campo E. SOX11, a
key oncogenic factor in mantle cell lym- phoma. Curr Opin Hematol. 2018;25(4): 299-306.
49. Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1996;87(10):4302- 4310.
50. Clot G, Jares P, Giné E, et al. A gene signa- ture that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood. 2018;132(4): 413-422.
764
haematologica | 2020; 105(3)